CNTA Centessa Pharmaceuticals plc
Price (delayed)
$16.02
Market cap
$1.82B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.55
Enterprise value
$1.77B
Highlights
CNTA's equity is up by 33% QoQ and by 3.7% YoY
Centessa Pharmaceuticals's quick ratio has increased by 31% QoQ and by 23% YoY
The net income has contracted by 14% from the previous quarter but it has grown by 9% YoY
The company's EPS rose by 14% YoY but it fell by 10% QoQ
The debt is up by 3.2% year-on-year
Key stats
What are the main financial stats of CNTA
Market
Valuations
Earnings
Shares outstanding
113.31M
Market cap
$1.82B
Enterprise value
$1.77B
Price to earnings (P/E)
N/A
Price to book (P/B)
6.31
Price to sales (P/S)
255.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
258.72
Revenue
$6.85M
EBIT
-$147.68M
EBITDA
-$146.72M
Free cash flow
-$146.38M
Per share
Balance sheet
Liquidity
EPS
-$1.55
Free cash flow per share
-$1.34
Book value per share
$2.54
Revenue per share
$0.06
TBVPS
$3.64
Total assets
$398.85M
Total liabilities
$111.88M
Debt
$85.1M
Equity
$286.97M
Working capital
$328.75M
Debt to equity
0.3
Current ratio
13.29
Quick ratio
11.02
Net debt/EBITDA
0.29
Margins
Efficiency
Dividend
EBITDA margin
-2,140.9%
Gross margin
100%
Net margin
-2,296%
Operating margin
-2,325.9%
Return on assets
-43%
Return on equity
-63.1%
Return on invested capital
-52.3%
Return on capital employed
-39.7%
Return on sales
-2,154.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CNTA stock price
How has the Centessa Pharmaceuticals stock price performed over time
Intraday
-1.6%
1 week
16.51%
1 month
28.16%
1 year
146.84%
YTD
101.26%
QTD
77.41%
Financial performance
How have Centessa Pharmaceuticals's revenue and profit performed over time
Revenue
$6.85M
Gross profit
$6.85M
Operating income
-$159.4M
Net income
-$157.35M
Gross margin
100%
Net margin
-2,296%
The operating income has grown by 17% YoY and by 2.9% from the previous quarter
The net income has contracted by 14% from the previous quarter but it has grown by 9% YoY
The net margin has declined by 14% since the previous quarter
Centessa Pharmaceuticals's operating margin has increased by 2.9% QoQ
Growth
What is Centessa Pharmaceuticals's growth rate over time
Valuation
What is Centessa Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.31
P/S
255.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
258.72
The company's EPS rose by 14% YoY but it fell by 10% QoQ
CNTA's price to book (P/B) is 78% higher than its last 4 quarters average of 3.6
CNTA's equity is up by 33% QoQ and by 3.7% YoY
Efficiency
How efficient is Centessa Pharmaceuticals business performance
Centessa Pharmaceuticals's return on invested capital has surged by 56% YoY and by 7% QoQ
The company's return on equity fell by 17% YoY and by 12% QoQ
Centessa Pharmaceuticals's return on assets has decreased by 13% QoQ and by 7% YoY
The company's return on sales rose by 3.8% QoQ
Dividends
What is CNTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CNTA.
Financial health
How did Centessa Pharmaceuticals financials performed over time
Centessa Pharmaceuticals's quick ratio has increased by 31% QoQ and by 23% YoY
CNTA's current ratio is up by 28% year-on-year and by 28% since the previous quarter
The debt is 70% smaller than the equity
CNTA's equity is up by 33% QoQ and by 3.7% YoY
Centessa Pharmaceuticals's debt to equity has decreased by 25% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.